Market data provided for informational purposes only. Not financial advice. Read disclaimers.
Market data provided for informational purposes only. Not financial advice. Read disclaimers.
Johnson & Johnson is one of the world's largest healthcare companies, operating across pharmaceuticals (Innovative Medicine) and medical devices (MedTech). Following the Kenvue consumer health spinoff in 2023, J&J is now a pure-play pharma and medtech company. Key drugs include Stelara (immunology), Darzalex (oncology), and Tremfya.
J&J's key risk is the Stelara patent cliff — biosimilar competition is expected to materially impact revenue. MedTech surgical robotics growth and the pharmaceutical pipeline (particularly in oncology and immunology) are offsetting factors.